242 related articles for article (PubMed ID: 38453446)
1. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
Qi C; Tian P; Li W
Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
3. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
4. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer.
Muthusamy B; Patil PD; Pennell NA
J Natl Compr Canc Netw; 2022 Aug; 20(8):953-961. PubMed ID: 35948038
[TBL] [Abstract][Full Text] [Related]
7. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Shu C; Zhu D; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967
[TBL] [Abstract][Full Text] [Related]
8. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
11. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
12. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Ni J; Huang M; Zhang L; Wu N; Bai CX; Chen LA; Liang J; Liu Q; Wang J; Wu YL; Zhang FC; Zhang SY; Chen C; Chen J; Fang WT; Gao SG; Hu J; Jiang T; Li SQ; Li HC; Liao YD; Liu Y; Liu DR; Liu HX; Liu JY; Liu LX; Wang MZ; Wang CL; Yang F; Yang Y; Zhang LJ; Zhi XY; Zhong WZ; Guan YZ; Guo XX; He CX; Li SL; Li Y; Liang NX; Lu FL; Lv C; Lv W; Si XY; Tan FW; Wang HP; Wang JS; Yan S; Yang HX; Zhu HJ; Zhuang JL; Zhuo ML
Thorac Cancer; 2021 May; 12(9):1469-1488. PubMed ID: 33787090
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction
of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].
Ji J; Zhang C; Peng L; Jiao W
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):92-101. PubMed ID: 35224962
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy.
Shi Y; Ma X; He D; Dong B; Qiao T
Front Immunol; 2023; 14():1213222. PubMed ID: 37600799
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
18. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
Chen XY; Yang F
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
[TBL] [Abstract][Full Text] [Related]
19. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang S; Mao Y
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Conroy MR; Dennehy C; Forde PM
Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]